Home>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Ketoprofen

Ketoprofen (Synonyms: (R,S)-Ketoprofen, 2-(3-benzoylphenyl)Propionic Acid)

Catalog No.GC13339

Dual COX1/2 inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Ketoprofen Chemical Structure

Cas No.: 22071-15-4

Size Price Stock Qty
10mM (in 1mL DMSO)
$35.00
In stock
50mg
$49.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC50s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively.

Ketoprofen (Compound 2) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC50s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively[1].

Ketoprofen (RP-19583) (0.32-10 mg/kg, s.c) dose-dependently inhibits acid-induced depression of nesting (IC50, 2.05 mg/kg), and reverses CFA-induced such depression at 0.1-10 mg/kg, with an IC50 of 0.18 mg/kg in mice[2].

References:
[1]. Palomer A, et al. Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorg Med Chem Lett. 2002 Feb 25;12(4):533-7.
[2]. Negus SS, et al. Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Pain. 2015 Jun;156(6):1153-60.

Reviews

Review for Ketoprofen

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ketoprofen

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.